Hybrid coronary revascularization in multivessel coronary artery disease: a systematic review.
Antonio NennaFrancesco NappiCristiano SpadaccioSalvatore Matteo GrecoMichele PilatoFrancesco StiloNunzio MontelioneVincenzo CataneseMario LusiniFrancesco SpinelliMassimo ChelloPublished in: Future cardiology (2022)
Aim: Hybrid coronary revascularization (HCR) for multivessel coronary artery disease (CAD) integrates coronary artery bypass grafting (CABG) and percutaneous intervention in a planned revascularization strategy. This systematic review summarizes the state of this art of this technique. Methods: Major databases searched until October 2021. Results: The available literature on HCR includes three randomized trials, ten meta-analysis and 27 retrospective studies. The greatest benefits are observed in patients with low-to-intermediate risk and less complex coronary anatomy; highly complex disease and the presence of risk factors favored conventional CABG in terms of adverse events and survival. Conclusion: HCR is an interesting approach for multivessel CAD but should not be considered a 'one-size-fits-all' procedure. Further studies will specify the subset of patients likely to benefit most from this hybrid approach.
Keyphrases
- coronary artery bypass grafting
- coronary artery disease
- systematic review
- percutaneous coronary intervention
- meta analyses
- cardiovascular events
- risk factors
- st segment elevation myocardial infarction
- end stage renal disease
- case control
- st elevation myocardial infarction
- randomized controlled trial
- chronic kidney disease
- ejection fraction
- newly diagnosed
- minimally invasive
- aortic stenosis
- prognostic factors
- peritoneal dialysis
- type diabetes
- coronary artery
- patient reported outcomes
- hiv infected
- ultrasound guided
- radiofrequency ablation
- antiretroviral therapy
- left ventricular
- free survival